Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175680 · ClinicalTrials.gov registry record · Phase 2
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02175680 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 43 participants.
The verdict
NCT02175680, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy. Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment, and one week overlap at the end of the treatment in subjects who do not experience virologic failure.
Interventions
- DRUG PRO 140
- OTHER Historical data
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-04-16 |
| Est. Completion | 2015-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02175680
The ClinicalTrials.gov registry entry for NCT02175680 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PRO 140 is the first listed.
NCT02175680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02175680 about?
NCT02175680 is a clinical study titled "Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection". This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy. Consenting subjects will be shifted from their combination antiretroviral regi...
What is the current status of trial NCT02175680?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-04-16. Estimated completion is 2015-02-02.
What interventions are being tested in trial NCT02175680?
The interventions under investigation include: PRO 140 (DRUG), Historical data (OTHER).
Who is sponsoring clinical trial NCT02175680?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.